In this review:
This review summarises evidence for the use of a basal plus regimen of a single prandial injection of insulin glulisine (Apidra®) added to basal insulin glargine (Lantus®) in patients with type 2 diabetes mellitus (T2DM) poorly controlled on oral antidiabetic drugs (OADs). Insulin glulisine and insulin glargine are approved for use in New Zealand for patients with T2DM who require insulin for the control of hyperglycaemia.
Download PDF